A trio of major drugmakers sparred with the Health and Human Services Department on Tuesday over obligations for providing cheap drugs under a federal program meant to service low-income Americans’ medical needs.
Attorneys for Novo Nordisk, Sanofi and AstraZeneca went before a three judge panel at the US Court of Appeals for the Third Circuit to dispute whether the government’s 340B program requires the companies to offer steeply discounted drugs through for-profit pharmacies that operate in contract with health-care providers participating in the program.
The battles hinge on whether the HHS or drugmakers have the final call on how many, ...